SCHEMBL6438856

SCHEMBL6438856

Nc1nc2nonc2nc1NN=Cc1ccc(-c2ccccc2)o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.51
MAPT P10636 12/20 0.48
KDM4E B2RXH2 7/20 0.48
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
LMNA P02545 4/20 0.48
ALDH1A1 P00352 6/20 0.45
POLB P06746 5/20 0.45
TDP1 Q9NUW8 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
HPGD P15428 5/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GFER P55789 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPK1 P28482 2/20 0.43
TSHR P16473 1/20 0.43
GAA P10253 2/20 0.42
THRB P10828 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6438851 1.00 BIRC5 (0.51) BIRC5MAPTKDM4EMEN1KMT2A
SCHEMBL6412951 0.89 PRMT5 (0.50) BIRC5MAPTKDM4EMEN1KMT2A
SCHEMBL6412944 0.89 PRMT5 (0.50) BIRC5MAPTKDM4EMEN1KMT2A
SCHEMBL6420375 0.86 BIRC5 (0.70) BIRC5MAPTKDM4EMEN1KMT2A
SCHEMBL6420380 0.86 BIRC5 (0.70) BIRC5MAPTKDM4EMEN1KMT2A
SCHEMBL6420773 0.85 BIRC5 (0.57) BIRC5MAPTKDM4EMEN1KMT2A
SCHEMBL6415263 0.83 MAPT (0.64) BIRC5MAPTKDM4EMEN1KMT2A
SCHEMBL6510185 0.82 BIRC5 (0.50) BIRC5MAPTKDM4EMEN1KMT2A
SCHEMBL6505849 0.81 BIRC5 (0.53) BIRC5MAPTKDM4EMEN1KMT2A
SCHEMBL6505842 0.81 BIRC5 (0.53) BIRC5MAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 BIRC5 2525/4885MAPT 4420/4885KDM4E 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.